SIT-话题@MedSci - 梅斯（MedSci）

#SIT#

113篇内容 | 2706人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1910562, encodeId=3986191056271, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=日本盐野义口服新冠病毒治疗药物Ensitrelvir（S-217622），治愈率达100%, objectType=article, longId=300218, objectId=1bf230021814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf230021814, replyNumber=0, likeNumber=0, createdTime=2022-06-11, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf230021814, moduleTitle=日本盐野义口服新冠病毒治疗药物Ensitrelvir（S-217622），治愈率达100%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1bf230021814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910563, encodeId=4ccd19105635a, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=盐野义新冠病毒特效药ensitrelvir拟提交国内上市申请，日本PMDA暂缓批准, objectType=article, longId=731414, objectId=8044e31414ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8044e31414ef, replyNumber=0, likeNumber=90, createdTime=2022-07-30, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8044e31414ef, moduleTitle=盐野义新冠病毒特效药ensitrelvir拟提交国内上市申请，日本PMDA暂缓批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8044e31414ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910560, encodeId=45e21910560d4, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=International Journal of Obesity：发胖先胖脑, objectType=article, longId=292208, objectId=e11229220872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11229220872, replyNumber=0, likeNumber=84, createdTime=2022-01-13, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11229220872, moduleTitle=International Journal of Obesity：发胖先胖脑, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e11229220872)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910558, encodeId=d81b1910558bd, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer, objectType=article, longId=221045, objectId=9e8a22104543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8a22104543, replyNumber=0, likeNumber=71, createdTime=2022-10-10, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8a22104543, moduleTitle=Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9e8a22104543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910561, encodeId=adac191056111, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=International Journal of Obesity：「躺平」就能瘦！不用运动节食，只需删除肥胖特定基因, objectType=article, longId=294385, objectId=a93d29438517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a93d29438517, replyNumber=0, likeNumber=110, createdTime=2022-09-16, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a93d29438517, moduleTitle=International Journal of Obesity：「躺平」就能瘦！不用运动节食，只需删除肥胖特定基因, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a93d29438517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910557, encodeId=e7aa191055efb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=221034, objectId=5e2522103406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e2522103406, replyNumber=0, likeNumber=122, createdTime=2022-04-08, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e2522103406, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5e2522103406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910559, encodeId=dca319105593e, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation, objectType=article, longId=221060, objectId=69b22210602c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b22210602c, replyNumber=0, likeNumber=62, createdTime=2022-09-21, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b22210602c, moduleTitle=Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=69b22210602c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910554, encodeId=56f7191055418, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=OCC 2021：POSITIVE研究结果发布，伊伐布雷定可有效改善我国慢性心衰患者的心率、心功能和生活质量！, objectType=article, longId=211941, objectId=ba39211941c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba39211941c1, replyNumber=0, likeNumber=98, createdTime=2021-11-22, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba39211941c1, moduleTitle=OCC 2021：POSITIVE研究结果发布，伊伐布雷定可有效改善我国慢性心衰患者的心率、心功能和生活质量！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ba39211941c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910556, encodeId=2a68191055678, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Pediatric Obesity：过度的电子屏幕时间与青春期前的肥胖有关, objectType=article, longId=213515, objectId=81a221351590, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81a221351590, replyNumber=0, likeNumber=139, createdTime=2022-05-20, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81a221351590, moduleTitle=Pediatric Obesity：过度的电子屏幕时间与青春期前的肥胖有关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=81a221351590)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910552, encodeId=de12191055294, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=SITC 2020：接受免疫疗法的癌症患者罹患COVID-19的风险并不高, objectType=article, longId=203276, objectId=bb852032e6c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb852032e6c9, replyNumber=0, likeNumber=103, createdTime=2021-05-15, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb852032e6c9, moduleTitle=SITC 2020：接受免疫疗法的癌症患者罹患COVID-19的风险并不高, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bb852032e6c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910551, encodeId=829c191055168, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=突破数字病理诊断关键技术瓶颈，飞利浦IntelliSite平台亮相CHINC 2020, objectType=article, longId=201739, objectId=03af201e39d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03af201e39d6, replyNumber=0, likeNumber=73, createdTime=2021-05-22, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03af201e39d6, moduleTitle=突破数字病理诊断关键技术瓶颈，飞利浦IntelliSite平台亮相CHINC 2020, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03af201e39d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910555, encodeId=5c89191055554, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Obesity：癌症与肥胖的因果关系, objectType=article, longId=212597, objectId=e02c21259ec0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e02c21259ec0, replyNumber=0, likeNumber=100, createdTime=2021-07-27, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e02c21259ec0, moduleTitle=Obesity：癌症与肥胖的因果关系, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e02c21259ec0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910550, encodeId=3b241910550d1, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, objectType=article, longId=201251, objectId=a8de201251f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de201251f5, replyNumber=0, likeNumber=76, createdTime=2021-06-19, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de201251f5, moduleTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a8de201251f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910544, encodeId=6dc51910544ec, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, objectType=article, longId=193578, objectId=2e2f1935e8e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e2f1935e8e9, replyNumber=0, likeNumber=97, createdTime=2021-02-06, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e2f1935e8e9, moduleTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e2f1935e8e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910545, encodeId=deb3191054586, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, objectType=article, longId=194616, objectId=2a611946163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a611946163b, replyNumber=0, likeNumber=89, createdTime=2020-09-14, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a611946163b, moduleTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a611946163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910553, encodeId=e269191055362, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Diabetes, Obesity and Metabolism：50万人数据显示，认知障碍可能开始于糖尿病前期 , objectType=article, longId=207100, objectId=f13c20e100bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f13c20e100bb, replyNumber=0, likeNumber=88, createdTime=2021-04-14, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f13c20e100bb, moduleTitle=Diabetes, Obesity and Metabolism：50万人数据显示，认知障碍可能开始于糖尿病前期 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f13c20e100bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910549, encodeId=402c19105493e, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Obesity 2020：Plenity（Gelesis100）治疗肥胖疗效明显, objectType=article, longId=200358, objectId=f931200358b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f931200358b4, replyNumber=0, likeNumber=92, createdTime=2021-08-14, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f931200358b4, moduleTitle=Obesity 2020：Plenity（Gelesis100）治疗肥胖疗效明显, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f931200358b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910547, encodeId=0cf2191054e34, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, objectType=article, longId=195473, objectId=16a61954e3e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a61954e3e1, replyNumber=0, likeNumber=121, createdTime=2021-05-03, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a61954e3e1, moduleTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=16a61954e3e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910541, encodeId=d5221910541cb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：真实世界中淋巴瘤免疫疗法的不良事件发生率高于临床试验, objectType=article, longId=187875, objectId=07d418e875f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07d418e875f9, replyNumber=0, likeNumber=87, createdTime=2020-02-25, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07d418e875f9, moduleTitle=2020年ASCO-SITC：真实世界中淋巴瘤免疫疗法的不良事件发生率高于临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=07d418e875f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910539, encodeId=53281910539d9, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：中性粒细胞与淋巴细胞的比例可预测晚期NSCLC患者接受免疫治疗的存活率, objectType=article, longId=187767, objectId=e71318e76739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71318e76739, replyNumber=0, likeNumber=109, createdTime=2020-02-15, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71318e76739, moduleTitle=2020年ASCO-SITC：中性粒细胞与淋巴细胞的比例可预测晚期NSCLC患者接受免疫治疗的存活率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e71318e76739)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SIT

2020-05-29

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

日本盐野义口服新冠病毒治疗药物Ensitrelvir（S-217622），治愈率达100%

2022-06-11

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

盐野义新冠病毒特效药ensitrelvir拟提交国内上市申请，日本PMDA暂缓批准

2022-07-30

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

International Journal of Obesity：发胖先胖脑

2022-01-13

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer

2022-10-10

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

International Journal of Obesity：「躺平」就能瘦！不用运动节食，只需删除肥胖特定基因

2022-09-16

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2022-04-08

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation

2022-09-21

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

OCC 2021：POSITIVE研究结果发布，伊伐布雷定可有效改善我国慢性心衰患者的心率、心功能和生活质量！

2021-11-22

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Pediatric Obesity：过度的电子屏幕时间与青春期前的肥胖有关

2022-05-20

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

SITC 2020：接受免疫疗法的癌症患者罹患COVID-19的风险并不高

2021-05-15

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

突破数字病理诊断关键技术瓶颈，飞利浦IntelliSite平台亮相CHINC 2020

2021-05-22

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Obesity：癌症与肥胖的因果关系

2021-07-27

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”

2021-06-19

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请

2021-02-06

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤

2020-09-14

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Diabetes, Obesity and Metabolism：50万人数据显示，认知障碍可能开始于糖尿病前期

2021-04-14

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Obesity 2020：Plenity（Gelesis100）治疗肥胖疗效明显

2021-08-14

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效

2021-05-03

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：真实世界中淋巴瘤免疫疗法的不良事件发生率高于临床试验

2020-02-25

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：中性粒细胞与淋巴细胞的比例可预测晚期NSCLC患者接受免疫治疗的存活率

2020-02-15

科室
- - 订阅+
  - 更多科室
工具
服务